MedTrace Logo

Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

NCT06510582 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2025-07-01

No results posted yet for this study

Summary

The goal of this clinical trial is to test whether infusing bevacizumab into the middle meningeal arteries can be used to treat chronic subdural hematomas (cSDH).

The main questions it aims to answer are:

* Is bevacizumab infusion safe in cSDH patients?
* Is bevacizumab infusion effective in treating cSDH?

Conditions

  • Chronic Subdural Hematoma

Interventions

DRUG

Bevacizumab 2 mg/kg

Single 2mg/kg dose of bevacizumab to treat unilateral cSDH

DRUG

Bevacizumab 4 mg/kg

Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH

Sponsors & Collaborators

  • Society of Vascular and Interventional Neurology

    collaborator UNKNOWN

  • The Cooper Health System

    lead OTHER

Principal Investigators

  • Jane Khalife, MD · The Cooper Health System

  • Ajith J Thomas, MD · The Cooper Health System

  • Manisha Koneru, MD · The Cooper Health System

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06510582 on ClinicalTrials.gov